Regulation of brain-derived neurotrophic factor and sorting receptor SORLA gene expression in dementia: a preliminary study (CROSBI ID 647112)
Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | domaća recenzija
Podaci o odgovornosti
Nikolac Perković, Matea ; Borovečki, Fran ; Filipčić, Igor ; Pivac, Nela
engleski
Regulation of brain-derived neurotrophic factor and sorting receptor SORLA gene expression in dementia: a preliminary study
Aim: Brain-derived neurotrophic factor (BDNF) is an important mediator of neuronal plasticity but it might also be a major regulator of SORLA transcription, a sorting receptor which is involved in regulated neuronal protein transport. This could be a way in which BDNF controls the trafficking of amyloid precursor protein (APP) between trans-Golgi network and early endosomes. Very little is known about factors that regulate the expression of SORLA. Therefore, the aim of this study was to provide a better insight into the role of BDNF as a possible regulator of SORLA transcription, since this process could play a key role in neurodegenerative processes. Methods: This preliminary study included 22 patients with Alzheimer’s disease (AD) or mild cognitive impairment (MCI). Peripheral blood mononuclear cells were separated from whole blood samples using Histopaque-1077 (Sigma) and the total RNA was isolated using the miRNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol. Quantification of gene expression was performed with LightCycler v2.0 (Roche Applied Science) using SYBR Premix Ex Taq II (Takara) and specific primers. The mRNA expression of each target gene was normalized to beta-actin (ACTB) in each sample, and quantitation of gene expression was determined by 2−ΔΔCT method. Results: The results showed no significant differences in gene expression of BDNF (t=1.98 ; df=20 ; p=0.062) and SORLA (t=-0.22 ; df=20 ; p=0.831) between subjects in the late stages of AD and patients with MCI. However, there was a non-significant trend (p=0.062) indicating a decreased BDNF expression in peripheral blood mononuclear cells of patients with AD, since the relative mRNA expression of BDNF, compared to ACTB, was reduced around 3 times (2- ΔΔCt=0.33) in patients diagnosed with AD compared to the individuals with MCI. In the case of SORLA there were no differences in the relative expression (2-ΔΔCt=1.05) of this gene between the two groups. Conclusions: This preliminary study may help to clarify the role of BDNF in dementia, since the results indicate that the relative expression of BDNF is lower in patients in the late stages of AD compared to the patients with MCI, but, unexpectedly, these differences do not correlate with the expression of SORLA.
BDNF, dementia, expression, SORLA
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
89-89.
2016.
nije evidentirano
objavljeno
Podaci o matičnoj publikaciji
Neurologia Croatica. Supplement
Šimić, Goran ; Mimica, Ninoslav
Zagreb: Denona
1331-5196
Podaci o skupu
Hrvatski kongres o Alzheimerovoj bolesti s međunarodnim sudjelovanjem, CROCAD-16 = Croatian Congress on Alzheimer’s Disease (CROCAD-16) with International Participation
poster
05.10.2016-08.10.2016
Tučepi, Hrvatska